Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer

Hui fang Hao, Munenori Takaoka, Xiao hong Bao, Zhi gang Wang, Yasuko Tomono, Kazufumi Sakurama, Toshiaki Ohara, Takuya Fukazawa, Tomoki Yamatsuji, Toshiyoshi Fujiwara, Yoshio Naomoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24. h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.

Original languageEnglish
Pages (from-to)744-749
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume423
Issue number4
DOIs
Publication statusPublished - Jul 13 2012

Fingerprint

Focal Adhesion Protein-Tyrosine Kinases
Oral Administration
Colorectal Neoplasms
Peritoneum
Small Interfering RNA
Tumors
Neoplasms
Bearings (structural)
Cells
HCT116 Cells
Biological Phenomena
TAE226
Integrins
Protein-Tyrosine Kinases
Colonic Neoplasms
Cell Movement
Cell Survival
Adhesion
Adenosine Triphosphate

Keywords

  • Anti-proliferation
  • Colon cancer
  • Focal adhesion kinase
  • Peritoneal dissemination
  • Prolonged survival
  • TAE226

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. / Hao, Hui fang; Takaoka, Munenori; Bao, Xiao hong; Wang, Zhi gang; Tomono, Yasuko; Sakurama, Kazufumi; Ohara, Toshiaki; Fukazawa, Takuya; Yamatsuji, Tomoki; Fujiwara, Toshiyoshi; Naomoto, Yoshio.

In: Biochemical and Biophysical Research Communications, Vol. 423, No. 4, 13.07.2012, p. 744-749.

Research output: Contribution to journalArticle

Hao, Hui fang ; Takaoka, Munenori ; Bao, Xiao hong ; Wang, Zhi gang ; Tomono, Yasuko ; Sakurama, Kazufumi ; Ohara, Toshiaki ; Fukazawa, Takuya ; Yamatsuji, Tomoki ; Fujiwara, Toshiyoshi ; Naomoto, Yoshio. / Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. In: Biochemical and Biophysical Research Communications. 2012 ; Vol. 423, No. 4. pp. 744-749.
@article{13cdb36aac42492a94f8b9500a9fb20b,
title = "Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer",
abstract = "Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24. h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.",
keywords = "Anti-proliferation, Colon cancer, Focal adhesion kinase, Peritoneal dissemination, Prolonged survival, TAE226",
author = "Hao, {Hui fang} and Munenori Takaoka and Bao, {Xiao hong} and Wang, {Zhi gang} and Yasuko Tomono and Kazufumi Sakurama and Toshiaki Ohara and Takuya Fukazawa and Tomoki Yamatsuji and Toshiyoshi Fujiwara and Yoshio Naomoto",
year = "2012",
month = "7",
day = "13",
doi = "10.1016/j.bbrc.2012.06.030",
language = "English",
volume = "423",
pages = "744--749",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer

AU - Hao, Hui fang

AU - Takaoka, Munenori

AU - Bao, Xiao hong

AU - Wang, Zhi gang

AU - Tomono, Yasuko

AU - Sakurama, Kazufumi

AU - Ohara, Toshiaki

AU - Fukazawa, Takuya

AU - Yamatsuji, Tomoki

AU - Fujiwara, Toshiyoshi

AU - Naomoto, Yoshio

PY - 2012/7/13

Y1 - 2012/7/13

N2 - Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24. h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.

AB - Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24. h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.

KW - Anti-proliferation

KW - Colon cancer

KW - Focal adhesion kinase

KW - Peritoneal dissemination

KW - Prolonged survival

KW - TAE226

UR - http://www.scopus.com/inward/record.url?scp=84863829748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863829748&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2012.06.030

DO - 10.1016/j.bbrc.2012.06.030

M3 - Article

C2 - 22705303

AN - SCOPUS:84863829748

VL - 423

SP - 744

EP - 749

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -